News Conference News ACC 2026 DIG-RHD: Digoxin Effective in Rheumatic Heart Disease Michael O'Riordan April 06, 2026
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017